Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04136002 · ClinicalTrials.gov registry record
Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode
A clinical trial of Colorectal Cancer, sponsored by Guardant Health.
- Completed
- Registry status
- 44,467
- Enrollment target
- 20
- Study locations
NCT04136002: Completed study of Colorectal Cancer, sponsored by Guardant Health.
NCT04136002 is a study of Colorectal Cancer that has completed, run by Guardant Health. The registered enrollment target is 44,467 participants, above the 1,428-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (3014% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04136002, a study of Colorectal Cancer, has completed, sponsored by Guardant Health.
- COMPLETED
- Registry status
- 44,467 participants
- Enrollment target
- 20
- Study locations
Study Summary
The ECLIPSE (Evaluation of the ctDNA LUNAR test in an Average Patient Screening Episode) study is a prospective, observational multi-site study without randomization. The primary objective of the study is to evaluate the performance characteristics of a blood-based ctDNA LUNAR-2 test to detect colorectal cancer in a screen-relevant, average risk population.
Primary Outcome
Sensitivity of colorectal cancer detection
Conditions Studied
Study Locations (20)
Arizona
- Hope Research Institute - Chandler
- Southeast Valley Gastroenterology - Chandler
- Prime Medical Group, LLC - Gilbert
- Hope Research Institute - Glendale
- GI Research Associates, LLC - Phoenix
- "Forty-Third Medical Associates Absolute Clinical Research" - Phoenix
- Del Sol Research Management, LLC - Tucson
- Novak Clinical Research - Tucson
- Del Sol Research Management, LLC - Tuscon
Alabama
- Pinnacle Research Group, LLC - Anniston
- Lakeview Clinical Research - Guntersville
- Medical Affiliated Research Center - Huntsville
- Jasper Summit Research LLC - Jasper
California
- Associated Gastroenterology Medical Group - Anaheim
- InSite Digestive Health Care - Arcadia
- Gastroenterology - Burlingame
- Ventura County Gastroenterology Medical Group - Camarillo
Arkansas
- Preferred Research Partners, Inc - Little Rock
- Premier Gastroenterology - Little Rock
- Arkansas Gastroenterology - North Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44,467 participants |
| Start Date | 2019-10-08 |
| Est. Completion | 2025-08-05 |
What the finished NCT04136002 record still lists
NCT04136002 is an observational study that tracks outcomes without assigning an intervention. Its 44,467 participants enrollment target places it among the larger protocols in the corpus, above the 1,428-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (3014% higher).
The record links to 1 condition, with Colorectal Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT04136002 names 20 study sites across 4 states, led by Arizona, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT04136002 about?
NCT04136002 is a clinical study titled "Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode". The ECLIPSE (Evaluation of the ctDNA LUNAR test in an Average Patient Screening Episode) study is a prospective, observational multi-site study without randomization. The primary objective of the study is to evaluate the performance characteristics of a blood-based ctDNA LUNAR-2 test to detect color...
What is the current status of trial NCT04136002?
This trial is currently completed. The enrollment target is 44,467 participants. The study started on 2019-10-08. Estimated completion is 2025-08-05.
What conditions does trial NCT04136002 study?
This clinical trial studies the following conditions: Colorectal Cancer.
Who is sponsoring clinical trial NCT04136002?
This trial is sponsored by Guardant Health, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04136002 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04136002's enrollment target sits among peer trials
44,467 4th of 381 higher than 378 of 381 other Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Cross-sectional Partnership to Improve Prevention and Health Equity Among African Americans
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
Resistance Exercise and Creatine in Colorectal Cancer
RECRUITING · NA
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05607732 · 45,257 participants · NA
Primary Care Detection of Cognitive Impairment Leveraging Health & Consumer Technologies in Underserved Communities: The MyCog Trial
- NCT06824350 · 45,450 participants · NA
Clean Trial - Chlorination to Reduce Enteric and Antibiotic Resistant Infections in Neonates
- NCT06597968 · 45,991 participants
Evaluating the Real World Performance of an AI Based Lung Nodule Detection Tool
- NCT03977402 · 47,500 participants
Total Cancer Care Protocol: A Lifetime Partnership With Patients Who Have or May be at Risk of Having Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI